Vivo Capital’s Akari Therapeutics AKTX Stock Holding History

Vivo Capital’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-432	Closed	-$699K	–	7
2019 Q2	$699K	Hold	432	–	–	0.07%	44
2019 Q1	$1.24M	Hold	432	–	–	0.12%	47
2018 Q4	$543K	Hold	432	–	–	0.07%	43
2018 Q3	$885K	Hold	432	–	–	0.09%	40
2018 Q2	$674K	Hold	432	–	–	0.09%	38
2018 Q1	$629K	Hold	432	–	–	0.09%	32
2017 Q4	$1.5M	Hold	432	–	–	0.32%	29
2017 Q3	$2.12M	Sell	432 -228	-35%	-$855K	0.43%	26
2017 Q2	$2.43M	Hold	660	–	–	0.61%	21
2017 Q1	$5.84M	Hold	660	–	–	1.72%	12
2016 Q4	$3.72M	Hold	660	–	–	1.22%	16
2016 Q3	$4.49M	Hold	660	–	–	1.4%	14
2016 Q2	$7.12M	Hold	660	–	–	1.94%	13
2016 Q1	$7.39M	Buy	+660	New	+$6.84M	1.85%	15

Other funds holding AKTX

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital's AKTX Position: Q3 2019 in Review

Vivo Capital sold out of Akari Therapeutics (AKTX) in Q3 2019, closing a stake of 432 shares — an estimated $699K sold.

Vivo Capital first reported a position in AKTX in Q1 2016 and held it in 14 quarters. The position peaked at $7.39M in Q1 2016. 10 funds tracked by Wall St. Rank hold AKTX as of Q3 2019.

Vivo Capital reported no remaining Akari Therapeutics position as of Q3 2019 after selling out during the quarter.
Vivo Capital sold 432 Akari Therapeutics shares in Q3 2019, an estimated $699K.
Vivo Capital first reported a position in Akari Therapeutics in Q1 2016 and held it in 14 quarters.
Vivo Capital's Akari Therapeutics position peaked at $7.39M in Q1 2016.
10 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2019.

Based on Vivo Capital's 13F filing for Q3 2019, filed 13 Nov 2019.